famili
interferon
ifn
protein
reach
potenti
envis
earli
discov
virologist
ifn
antivir
spectrum
clinic
effect
rna
dna
virus
also
prototyp
biolog
respons
modifi
oncolog
show
effect
suppress
manifest
multipl
sclerosi
studi
ifn
result
fundament
insight
cellular
signal
mechan
gene
transcript
innat
acquir
immun
elucid
multitud
ifninduc
gene
well
drug
develop
strategi
target
ifn
product
via
activ
tolllik
receptor
tlr
almost
certainli
lead
newer
efficaci
therapeut
goal
offer
molecular
clinic
perspect
enabl
ifn
tlr
agonist
induc
reach
full
clinic
potenti
natur
review
drug
discoveri
volum
decemb
discoveri
molecular
understand
cell
ular
mechan
clinic
use
interferon
ifn
major
advanc
biomedicin
past
year
famili
secret
autocrin
para
crine
protein
stimul
intracellular
intercellular
network
regul
resist
viral
infect
enhanc
innat
acquir
immun
respons
modul
normal
tumour
cell
surviv
death
discoveri
ref
soon
appr
ciat
ifn
critic
import
health
anim
human
ifn
system
potenti
therapi
infect
rna
dna
virus
timelin
howev
advanc
molecular
biolog
decad
later
requir
promis
could
realiz
saw
introduct
clinic
first
pharmaceut
product
bud
biotechnolog
industri
importantli
demonstr
effect
ifn
viral
diseas
cancer
also
multipl
sclerosi
ms
mark
expans
clinic
applic
regulatori
approv
world
wide
understand
molecular
event
influenc
biolog
action
current
studi
led
new
insight
ifn
fundament
compon
innat
immun
system
addit
studi
reveal
ifn
product
induc
toll
like
receptor
tlr
action
ifnstimul
gene
isg
identif
viral
mechan
resist
action
potent
protein
mutat
suppress
gene
product
ifn
system
malign
cell
may
affect
initi
progress
cancer
bind
highaffin
receptor
ifn
initi
signal
cascad
signal
protein
also
activ
cytokin
first
identifi
studi
ifn
cellular
action
mediat
specif
isg
underli
antivir
effect
well
immunoregu
latori
antitumour
effect
futur
drug
could
act
molecular
activ
isg
mani
exist
latent
state
agonist
tlr
might
expect
potent
antivir
antitumour
andor
immunomodulatori
effect
publish
paper
offer
perspect
focu
human
ifn
stimul
futur
investig
import
question
although
ifn
function
integr
system
conceptu
help
consid
product
medi
ate
tlr
activ
action
mediat
jakstat
janu
kinasesign
transduc
activ
transcript
signal
pathway
product
ifn
import
understand
role
ifn
innat
immun
effect
relat
dissect
lie
futur
mechan
action
applic
highlight
initi
pivot
discoveri
recent
find
conceptu
import
review
ifn
induc
cellular
action
ifn
isg
human
therapeut
applic
summar
import
que
tion
biomedicin
drug
clinic
develop
initi
synthesi
induc
product
ifn
vitro
vivo
transient
requir
stimul
virus
microbi
product
chemic
induc
cours
discoveri
ifn
either
live
heatinactiv
influenza
virus
initi
identifi
induc
subsequ
microbi
product
includ
bacteria
proto
zoa
rna
dna
virus
also
recogn
induc
ifn
also
shown
microbi
nucleic
acid
lipid
polysaccharid
protein
trigger
induc
tion
ifn
activ
tlr
fig
earli
pivot
discoveri
identifi
doublestrand
ds
rna
natur
synthet
potent
induc
lead
simplist
paradigm
virus
induc
ifn
produc
dsrna
realiti
one
viral
gene
product
respons
induct
nonetheless
dissect
cellular
respons
lead
induct
spearhead
analysi
dsrnamedi
signal
pathway
dsrna
recogn
present
mostli
endosom
membran
also
two
cytoplasm
rna
helicas
retino
acidinduc
gene
rigi
melanoma
differenti
associ
protein
fig
cytoplasm
protein
also
recogn
singlestrand
ss
rna
mice
ref
rigi
ref
gene
disrupt
suscept
viru
infect
howev
rel
import
three
protein
inhibitori
activ
vari
immun
defenc
differ
virus
surprisingli
presenc
enhanc
pathogenesi
mice
infect
influenza
viru
west
nile
viru
adaptor
protein
signal
tlr
adapt
molecul
trif
wherea
mitochondri
protein
stimul
also
known
visa
adaptor
rigi
trif
recruit
inhibitor
nuclear
kinas
ikk
tankbind
kinas
common
activ
kinas
nucleic
acid
ssrna
act
bacteri
oligodeoxyribonucleotid
act
also
potent
induc
bacteri
lipopolysaccharid
induc
ifn
also
recruit
trif
viral
glycoprotein
bind
activ
dif
ferent
tlr
addit
cytoplasm
receptor
exist
recogn
viral
dna
ifn
gene
normal
transcript
silent
induc
bind
tlractiv
transcript
factor
promot
transcript
induct
model
experiment
sy
tem
defin
interact
transcript
factor
enhanceosom
multiprotein
complex
dna
import
transcript
factor
induct
protein
ifn
regulatori
factor
irf
specifi
calli
famili
irf
activ
kinas
activ
irf
dimer
transloc
nucleu
ikk
protein
kinas
complex
phosphoryl
releas
activ
phosphoryl
kinas
evad
ifn
system
virus
evolv
mani
mechan
block
ifn
synthesi
action
act
almost
everi
step
signal
pathway
exampl
hepat
c
viru
hcv
encod
proteas
cleav
mitochondri
membran
block
signal
antivir
unit
concentr
interferon
requir
inhibit
viru
replic
vitro
intern
standard
provid
refer
base
major
interferon
type
establish
antivir
state
inter
action
rigi
convers
patient
defect
product
type
ifn
due
mutat
gene
highli
suscept
herp
simplex
viru
enceph
develop
smallmolecul
activ
induct
begin
howev
delin
respons
signal
pathway
identifi
mani
target
protein
cpg
oligonucleotid
activ
ref
quinolinamin
imiquimod
analogu
activ
ref
dmxaa
induc
ifn
synthesi
tlrindepend
pathway
develop
chemic
modul
select
activ
ifn
synthesi
block
synthesi
inflammatori
cytokin
could
broad
therapeut
potenti
realiz
ifn
constitut
protein
famili
aros
initi
definit
antigen
differ
human
fibroblast
leukocyt
ifn
although
protein
purif
studi
sug
gest
potenti
multigen
natur
firmli
establish
clone
accomplish
help
solidifi
financi
futur
nascent
biotechnolog
industri
number
function
gene
identifi
encod
type
ifn
grown
subsequ
nonallel
gene
describ
human
lack
intron
cluster
chromosom
ref
type
ifn
plu
addit
synthet
concen
su
sequenc
also
addit
minor
allel
variant
wherea
one
type
fig
among
mammal
number
type
ifn
gene
variabl
uniqu
type
exampl
occur
pig
rumin
other
devoid
particular
type
exampl
mice
consist
univers
biolog
definit
ifn
protein
induc
rel
speciesspecif
antivir
effect
type
ifn
mostli
nonglycosyl
pro
tein
amino
acid
share
homolog
rang
within
speci
essenti
rel
high
specif
potenc
antivir
unit
per
mg
protein
although
type
ifn
qualit
quantita
tive
differ
antivir
action
reason
origin
mainten
evolu
tion
relat
protein
unknown
mamma
lian
speci
retain
howev
least
one
one
human
express
seem
tissu
specif
cell
abl
produc
ifn
monocytederiv
dendrit
cell
viral
infect
induc
express
subtyp
stimul
induc
mostli
emphas
differ
promot
sequenc
gene
govern
respons
differ
induc
type
ifn
belong
helic
cytokin
famili
secondari
structur
five
bundl
held
posit
two
disulphid
bond
act
cellsurfac
receptor
compos
two
ubiquit
express
transmembran
protein
ifn
receptor
gene
cluster
chromosom
associ
two
cytoplasm
tyrosin
kinas
ref
fig
format
ifnreceptor
complex
involv
one
side
ifn
protein
interact
region
form
hing
two
fibronectin
type
iii
fniii
domain
fig
bind
affin
nanomolar
rang
bind
ifn
affin
weaker
bind
site
locat
opposit
bind
ing
site
bind
studi
consist
ternari
complex
ifn
stoichiometri
similar
ident
archi
tectur
type
ifn
ternari
complex
assembl
twostep
process
ligand
bind
first
one
ifnar
recruit
second
identifi
inter
action
two
ifnar
affin
gener
much
higher
bind
pathway
ifn
bind
first
higher
probabl
howev
low
affin
relev
revers
bind
pathway
could
lead
differ
cellular
effect
confirm
differ
struc
ture
ifnreceptor
complex
account
differenti
activ
type
ifn
bodi
argument
includ
studi
activ
engin
ifn
suggest
differenti
affin
ifnar
thu
ternari
complex
stabil
govern
differenti
biolog
activ
cellsurfac
concentr
ifnar
later
organ
microdomain
could
also
import
cellular
paramet
shape
respons
individu
ifn
similar
chang
receptor
organiza
tion
may
also
account
increas
suscept
hbv
infect
occur
polymorph
class
ii
cytokin
receptor
gene
singl
glycosyl
protein
amino
acid
design
type
ii
ifn
di
tant
aminoacid
sequenc
homolog
type
ifn
product
natur
killer
nk
activ
cell
like
type
ifn
bind
two
class
ii
cytokin
receptor
protein
ligand
bound
form
complex
two
receptor
protein
link
antiparallel
homodim
fig
receptor
map
chromosom
bind
domain
dock
site
contain
bind
ing
domain
map
chromosom
cluster
also
contain
interleukin
receptor
also
known
although
constitut
present
cell
tightli
regul
less
wide
express
promot
polymorph
andor
mutat
within
chain
associ
increas
suscept
malaria
mycobacteria
patient
defect
reconstitut
marrow
transplant
type
iii
ifn
famili
three
subtyp
coproduc
activ
main
signal
pathway
type
ifn
evolv
complet
differ
receptor
structur
fig
initi
studi
identifi
sever
gene
induc
type
ifn
analysi
promot
identifi
conserv
dna
element
protein
bound
element
treatment
type
ifn
purifi
identifi
identifi
compon
ifndepend
signal
ling
cascad
promot
element
gene
use
drive
ifndepend
express
guanin
phosphoribosyl
transferas
cell
respond
ifn
select
follow
chemic
mutagenesi
sever
mutant
cell
line
obtain
lack
protein
essenti
signal
exampl
mutant
shown
complemen
tation
lack
tyrosin
kinas
ref
subsequ
seven
stat
four
jak
famili
member
identifi
transcript
factor
tyrosin
kinas
shown
essenti
respons
ifn
also
cytokin
growth
factor
well
minimum
requir
respons
type
ifn
heterodimer
ifn
receptor
tyrosin
kinas
reciproc
transphosphoryl
receptor
chain
activ
phosphoryl
respons
signal
unphosphoryl
fig
transcript
respons
ifndepend
signal
initi
highaffin
bind
specif
palindrom
promot
sequenc
trimer
complex
respons
requir
two
receptor
protein
kinas
bind
competit
phosphotyrosin
residu
bind
greatli
favour
although
initi
work
carri
primarili
human
fibroblast
recent
studi
identifi
addit
complex
allow
individu
cell
type
respond
activ
differ
stat
respons
ifn
review
ref
analysi
defect
ifn
system
identifi
germlin
mutat
human
result
defici
enhanc
suscepti
biliti
infect
virus
although
mous
use
model
human
defect
alway
ident
effect
result
target
dele
tion
gene
mice
upon
activ
receptor
jak
undergo
autophosphoryl
transphosphoryl
increas
activ
phosphoryl
ifn
receptor
final
stat
howev
kinas
activ
jak
suffici
explain
nuanc
signal
tissuespecif
differ
activ
addit
protein
kinas
probabl
con
tribut
differenti
respons
variou
cell
singl
type
ifn
least
cell
type
subunit
phosphatidylinositol
associ
activ
ifn
lead
akt
phosphoryl
express
chemokin
cxc
motif
ligand
gene
encod
import
chemokin
type
ifn
also
activ
inactiv
block
induct
encod
tumour
necrosi
factorrel
apoptosisinduc
ligand
encod
chemo
kine
also
known
peptid
kda
primari
leukocyt
import
function
activ
protein
serin
kinas
protein
kinas
c
pkc
respons
ifndepend
signal
phosphoryl
directli
indirectli
transcript
factor
serin
phosphoryl
respons
kinas
cascad
mitogenactiv
protein
kinas
kinas
also
known
variat
acti
vation
differ
pkc
mkk
protein
differ
cell
ifndepend
activ
extracellular
respons
kinas
erk
stimul
pho
phoryl
possibl
respect
activ
transcript
factor
may
either
drive
gene
express
independ
activ
stat
cooper
activ
stat
certain
promot
fig
convers
transcript
initia
ted
phosphoryl
stat
proceed
indefi
nite
homeostasi
balanc
result
action
phosphatas
famili
isg
suppressor
cytokin
signal
soc
protein
soc
inhibit
receptor
signal
directli
inhibit
jak
target
receptor
complex
proteasom
degrad
prior
exposur
cytokin
condit
cell
respond
convers
ifn
condit
respons
cytokin
excel
exampl
effect
prior
exposur
human
macrophag
chang
respons
activ
activ
ref
although
reductionist
scientist
tend
studi
respons
cell
cultur
treatment
ifn
alon
situat
vivo
obvious
much
complex
also
known
melanoma
differenti
associ
protein
also
known
recogn
dsrna
lumen
endosom
caus
phosphoryl
specif
tyrosin
residu
unidentifi
protein
tyrosin
kinas
ptk
dimer
bind
activ
signal
complex
assembl
tlr
adaptor
molecul
trif
two
major
pathway
bifurc
trif
one
compos
tumour
necrosi
factor
tnf
receptorassoci
factor
tankbind
kinas
lead
phosphoryl
transcript
factor
ifn
regulatori
factor
requir
phosphoryl
phosphatidylinositol
akt
pathway
full
activ
initi
bind
phosphoryl
branch
act
transform
growth
kinas
also
known
lead
activ
nuclear
jun
activ
transcript
factor
transcript
factor
activ
transcript
factor
transloc
cytoplasm
nucleu
bind
cognat
site
promot
target
gene
singli
combin
induc
transcript
b
cytoplasm
rna
helicas
rigi
recogn
dsrna
triphosphoryl
singlestrand
ss
rna
use
mitochondri
membranebound
protein
stimul
also
known
visa
specif
adaptor
function
like
trif
activ
transcript
factor
lead
induct
similar
gene
addit
caus
apoptosi
activ
caspas
interact
fadd
solid
arrow
denot
step
fulli
delin
stippl
arrow
show
step
contain
yet
unknown
intermediari
interact
protein
chemokin
cc
motif
ligand
chemokin
cxc
motif
ligand
interferoninduc
protein
tetratricopeptid
repeat
ikk
inhibitor
kinas
sele
selectin
e
endotheli
adhes
molecul
type
type
activ
addit
role
cytokineactiv
transcript
factor
activ
respons
type
type
ii
ifn
activ
respons
cytokin
drive
essen
tialli
opposit
biolog
respons
larg
signaldepend
chang
concentr
affect
rel
acti
vation
signal
inde
increas
ratio
treatment
patient
melanoma
correl
surviv
anoth
consequ
cytokinedepend
increas
stat
express
unphosphoryl
import
func
tion
quit
distinct
phosphoryl
ate
protein
exampl
unphosphoryl
activ
subset
gene
form
complex
thu
role
stat
signal
receptor
bind
expand
kinaseactiv
transcript
factor
protein
even
absenc
ligand
activ
activ
transcript
partici
pate
celltyp
specif
result
divers
pattern
isg
induct
differ
cell
type
respons
singl
ifn
isg
molecular
mechan
antivir
action
isg
divers
group
gene
mani
function
celltyp
signal
variat
discuss
mediat
bio
logic
therapeut
effect
ifn
stimul
tabl
studi
mode
action
result
fundament
discoveri
concern
translat
control
regul
rna
stabil
edit
protein
transport
turnov
furthermor
protein
induc
upon
ifn
stimul
especi
activ
inhibit
vivo
target
highthroughput
screen
identif
new
modul
ifn
system
exampl
syn
thetas
oass
ribonucleas
l
rnasel
inhibit
broad
rang
rna
virus
viral
dsrna
directli
activ
one
sever
human
oa
protein
produc
uniqu
link
oligoadenyl
base
atp
wellestablish
function
activ
ubiquit
latent
enzym
rnasel
bind
rnasel
induc
monomer
inact
rnasel
dimer
potent
endoribonucleas
cleav
singlestrand
region
rna
side
upup
upap
dinucleotid
oasrnasel
pathway
inhibit
replic
encephalomyocard
viru
coxsacki
viru
west
nile
viru
retrovirus
hcv
furthermor
degrad
cellular
mrna
rrna
rnasel
damag
host
cell
machineri
requir
viral
replic
result
apoptosi
contrib
ute
antivir
antitumour
action
rnasel
also
cleav
selfrna
small
degrad
product
activ
recognit
receptor
rigi
induc
similar
non
self
viral
rna
thu
perpetu
amplifi
product
highthroughput
screen
result
identif
small
molecul
activ
rnasel
produc
broadspectrum
antivir
effect
dsrnaactiv
protein
kinas
pkr
oa
first
enzym
identifi
uniqu
respond
ifn
pkr
serinethreonin
kinas
mediat
translat
transcript
control
respons
dsrna
signal
addi
tion
cellular
protein
pact
also
known
prkra
activ
pkr
absenc
dsrna
pkr
mediat
translat
control
phosphoryl
protein
synthesi
initi
factor
result
inac
tive
complex
recycl
factor
event
produc
global
inhibit
protein
synthesi
block
viral
replic
full
amplif
viralinduc
cellular
stress
respons
mani
virus
howev
evad
pkr
rang
strategi
bind
sequest
dsrna
thu
depriv
pkr
activ
inhibit
kinas
activ
anoth
isg
famili
influenc
translat
strongli
induc
protein
ifit
gene
prod
uct
two
inhibit
protein
synthesi
block
action
translat
initi
factor
ref
bind
differ
subunit
type
interferon
ifn
pig
rumin
interact
ifn
receptor
type
ii
receptor
type
iii
receptor
also
known
interleukin
receptor
also
known
type
ii
antiparallel
homodim
exhibit
twofold
axi
symmetri
bind
two
receptor
chain
assembl
complex
stabil
two
chain
receptor
associ
two
kinas
jak
famili
type
iii
ifn
type
ii
ifn
ifn
receptor
chain
belong
class
helic
cytokin
receptor
famili
defin
structur
extracellular
domain
member
approxim
amino
acid
structur
two
subdomain
amino
acid
fibronectin
type
iii
modul
structur
seven
arrang
aminoacid
domain
usual
contain
ligand
bind
site
classic
repres
famili
atyp
extracellular
domain
duplic
ga
site
ifn
regulatori
factor
ifnstimul
gene
factor
refer
complex
isr
ifnstimul
respons
element
p
phosphat
signal
transduc
activ
transcript
ifn
jak
cytokin
jak
jak
caspas
group
enzym
role
promot
apoptosi
program
cell
death
inhibit
enzym
might
use
combat
cell
tissu
damag
condit
myocardi
infarct
stroke
inflammatori
diseas
neurodegen
diseas
augment
enzym
product
proapoptot
protein
might
use
combat
prolif
condit
cancer
block
divers
function
hcv
mrna
translat
inhibit
strongli
cellular
mrna
initi
intern
ribo
entri
site
ire
mediat
capmedi
thu
select
inhibit
viral
protein
synthesi
isgencod
antivir
protein
mx
identi
fie
resist
mous
strain
influenza
virus
orthomyxoviru
resist
gene
mx
protein
larg
kda
gtpase
dynamin
superfamili
selfassembl
bind
viral
nucleocapsid
interfer
intracellular
traffick
activ
viral
polymeras
thu
inhibit
replic
mani
rna
virus
includ
influenza
measl
virus
human
homo
logu
mxa
cytoplasm
protein
associ
intracellular
membran
encod
ubiquitinlik
kda
protein
modifi
protein
process
known
isgyl
inhibit
releas
cell
mimick
effect
ifn
infect
influenza
herp
sindbi
virus
antivir
mechan
vivo
unknown
could
relat
cytokinelik
properti
abil
conju
gate
modifi
function
cellular
viral
protein
also
target
gene
dysregul
isg
pathway
occur
mani
type
cancer
suggest
addit
role
tumorigenesi
phospholipid
scramblas
protein
implic
ca
depend
reorgan
plasma
membran
phospholipid
either
insert
plasma
membran
bind
dna
nucleu
depend
palmyitoyl
anti
viral
activ
possibl
result
enhanc
transcript
subset
isg
isg
contribut
apoptosi
therefor
probabl
antivir
antitumour
effect
ifn
although
mani
isg
promot
apoptosi
promot
cell
surviv
exampl
isg
local
mitochondria
anti
apoptot
action
includ
inhibit
ref
relat
isg
encod
promot
agedepend
resist
alphaviru
enceph
mice
without
affect
either
level
apoptosi
viral
yield
addit
isg
f
c
u
n
n
v
r
l
induc
nitric
oxid
synthas
ino
induc
haem
contain
enzym
produc
nitric
oxid
respons
inflammatori
signal
protein
function
nuclear
transport
protein
rna
probabl
confirm
antivir
activ
includ
guanylatebind
protein
ase
encod
promyelocyt
leukaemia
protein
pml
adenosin
deaminas
endoplasm
reticulumassoci
protein
viperin
inhibit
human
cytomegaloviru
induc
ibl
nitric
oxid
synthas
ino
nucleoporin
ref
final
mani
ifnpathway
signal
protein
isg
thu
provid
autocrin
loop
amplifi
ifn
respons
exampl
rigi
isg
high
level
transcript
induct
still
poorli
character
function
could
prove
critic
mediat
antivir
action
biolog
effect
ifn
mediat
action
isg
tabl
research
understand
function
protein
product
may
lead
efficaci
antivir
therapeut
addit
direct
inhibit
viral
replic
isg
second
level
ifn
action
augment
adapt
acquir
immun
respons
earli
warn
pathogen
presenc
deliv
tissueassoci
circul
dendrit
cell
one
type
plasmacytoid
dendrit
cell
circul
type
ifnproduc
cell
addit
tlr
activ
cell
site
pathogen
invas
replic
respons
culmin
dendrit
cellmedi
present
cell
pathogenderiv
peptid
fragment
bound
surfac
major
histocompat
complex
mhc
class
ii
molecul
mhc
class
ii
protein
select
upregu
late
wherea
type
ifn
fail
owe
induct
ref
infect
cell
display
peptid
fragment
associ
mhc
class
molecul
surfac
recogn
subsequ
elimin
cell
therebi
clear
viru
either
type
ifn
mark
edli
upregul
mhc
class
idepend
antigen
presenta
tion
addit
mhc
molecul
isg
involv
antigen
process
includ
lysosom
membran
permeabil
lmp
compon
proteasom
transport
antigen
process
tap
shuttl
peptid
endoplasm
reticulum
load
onto
nascent
mhc
class
protein
ifn
also
promot
accumul
leukocyt
site
pathogen
invas
specif
ifn
along
cytokin
strongli
pro
mote
express
vascular
adhes
molecul
includ
intracellular
adhes
molecul
furthermor
ifn
induc
product
chemotact
rnasel
ribonucleas
l
signal
transduc
activ
transcript
kda
tumour
necrosi
factorrel
apoptosisinduc
ligand
also
known
viperin
also
known
xlink
inhibitor
apoptosisassoci
factor
xiap
xlink
inhibitor
apoptosi
protein
also
known
cytokin
chemokin
particip
leukocyt
recruit
exampl
three
close
relat
chemo
kine
involv
accumul
activ
cell
macrophag
isg
also
known
mig
monokin
induc
also
known
kd
induc
protein
also
known
itac
interferoninduc
tcell
attract
true
name
chemokin
express
absenc
ifn
signal
develop
adapt
immun
respons
produc
earli
warn
nk
cell
activ
cell
govern
express
class
ii
transactiv
ciita
master
regul
transcrip
tion
mhc
class
ii
molecul
well
associ
invari
chain
help
stabil
mhc
class
ii
heterodim
hladm
catalys
di
placement
invari
chain
mhc
class
ii
peptid
bind
site
matur
mhc
class
iipeptid
conjug
final
insert
plasma
membran
final
substanti
import
host
respons
viru
ifnmedi
activa
tion
cytotox
effector
function
among
cell
innat
adapt
immun
includ
nk
cell
dendrit
cell
macrophag
cell
inde
properti
stimul
macrophag
contribut
substanti
recognit
biolog
import
lymphokin
differ
ifn
human
therapeut
applic
base
preclin
studi
broad
spectrum
inhibi
tion
viru
replic
ifn
initi
investig
antivir
activ
rna
dna
virus
clinic
effect
establish
develop
rel
specif
low
molecular
mass
antivir
larg
supplant
broad
applic
except
hbv
hcv
chronic
infect
first
us
food
drug
administr
fda
approv
ifn
howev
viru
infect
cancer
driven
interest
creat
public
result
ing
effect
american
cancer
societi
trial
subsequ
placebocontrol
random
trial
establish
effect
relap
ing
remit
ms
appar
paradox
term
mechanist
understand
ifn
action
ifn
discuss
gener
immun
augment
rather
immunosuppress
present
number
drug
design
target
differ
compon
ifn
system
differ
therapeut
indic
fig
virus
recognit
hbv
often
caus
chronic
infect
lead
cirrhosi
hepatocellular
carcinoma
suggest
infect
patient
might
benefit
ifn
initi
clinic
trial
impur
suggest
benefit
studi
impur
less
promis
lowdos
studi
follow
howev
higher
dose
recombin
ifn
becam
avail
confirm
benefici
effect
hbv
chronic
infect
evolv
hepat
e
antigen
hbeag
posit
quiescent
virus
escap
inhibit
convers
immunotoler
immunoact
phase
enhanc
immun
elimin
infect
hepatocyt
mani
immun
respons
caus
suppress
viral
replic
hbeag
loss
quiescent
phase
healthi
carriag
may
ensu
diseas
reactiv
common
hbeag
neg
diseas
hbeagposit
earli
hbv
infec
tion
ifn
particularli
effect
howev
immunoact
chronic
phase
hbv
sensit
ongo
immun
respons
aug
ment
lead
quiescent
hbeagneg
diseas
patient
roferona
hoffmann
laroch
introna
scheringplough
usual
form
longact
pegyl
version
wide
use
treat
hbeagposit
hbv
infect
also
use
hbeagneg
diseas
develop
viral
mutat
permit
viral
reactiv
follow
hbeag
loss
ifn
reduc
viraemia
usual
induc
host
respons
drug
withdraw
often
lead
diseas
recurr
ever
proport
patient
approxim
prolong
period
viral
suppress
therapi
chronic
hbv
infect
illustr
two
compl
mentari
activ
ifn
hbeagposit
diseas
ifn
increas
immun
respons
wherea
hbeag
neg
diseas
ifn
act
direct
antivir
late
nona
nonb
hepat
post
transfus
hepat
effect
treat
ifn
subsequ
studi
identifi
caus
agent
hcv
initi
clinic
studi
result
sustain
cur
virolog
respons
patient
respons
rate
monotherapi
chronic
hcv
infect
transform
combin
use
weak
antivir
ribavirin
patient
respond
result
mimic
studi
hsv
kerat
therapi
combin
ifn
weak
antivir
agent
acyclovir
synergist
therapi
chronic
hcv
infect
evolv
current
regim
com
monli
use
longact
pegyl
plu
ribavirin
cure
patient
possibl
result
select
rnasel
cleavag
site
genom
inhibit
pkr
effect
much
less
geno
type
genotyp
hcv
addit
hbv
hcv
infect
chronic
viral
infect
effect
treat
sy
temic
topic
reduc
viru
titr
decreas
clinic
manifest
herp
zoster
hsv
cytomegaloviru
infect
almost
simultan
introduct
acyclovir
analogu
howev
prove
greater
clinic
efficaci
reduc
side
effect
end
clinic
develop
ment
ifn
indic
papilloma
viru
infec
tion
skin
larynx
genit
found
respond
regress
wart
upon
either
intralesion
system
administr
compar
placebo
use
therapeut
effect
result
patient
extens
refractori
diseas
perman
erad
infrequ
studi
howev
establish
basi
use
ifninduc
agonist
imiquimod
topic
genit
wart
decreas
hpv
dna
complet
studi
hiv
viru
recoveri
clinic
manifest
earli
late
stage
reduc
howev
effect
azidothymidin
proteas
inhibitor
enhanc
ifn
use
combin
adequ
quantiti
human
ifn
becam
avail
abl
recombin
dna
product
prophylaxi
treatment
acut
respiratori
viru
infect
assess
reduct
viru
yield
infect
frequenc
symptom
score
result
administr
intranas
ifn
experiment
challeng
infect
rhinovirus
influenza
virus
coronavirus
prophylact
efficaci
natur
rhinoviru
cold
fam
ili
work
set
also
identifi
howev
result
nasal
eros
bleed
result
mucos
irrit
symptom
score
field
condit
significantli
higher
treat
patient
compar
placebo
case
base
use
set
sever
acut
respiratori
syndrom
sar
epidem
suggest
clinic
effect
ness
consensu
sequenc
type
ifn
coronaviru
aetiolog
agent
find
preclin
clinic
antivir
effect
topic
andor
highdos
administr
suggest
ifn
might
prophylact
therapeut
effect
sar
influenza
viru
pandem
patient
ms
inflammatori
demyelin
disord
cen
tral
nervou
system
diseas
begin
approxim
annual
episod
transient
neurolog
dysfunct
relapsingremit
ms
rrm
initi
studi
ifn
follow
tissuecultur
studi
sug
gest
cell
ms
patient
secret
less
ifn
like
activ
follow
viral
induct
control
find
combin
notion
slow
chronic
viral
infect
might
caus
result
evalu
use
intrathec
impur
therapi
identifi
reduct
relaps
howev
subsequ
clinic
trial
either
inconclus
detriment
recombin
given
subcutan
ousli
random
placebocontrol
trial
rrm
reduc
relaps
third
result
mark
reduct
subclin
diseas
assess
magnet
reson
imag
mri
report
usher
modern
age
ms
therapeut
show
ing
natur
histori
ms
could
modifi
document
clinic
benefici
demonstr
mri
lesion
use
surrog
clinic
effect
wide
use
ms
drug
develop
common
clinic
practic
initi
betaferonbetaserom
bayer
scheringchiron
avonex
biogen
idec
rebif
merck
serono
medic
compar
efficaci
time
diagnosi
attack
decreas
number
new
activ
mri
lesion
reflect
inflamm
often
reduc
soon
initi
longterm
clinic
benefit
consid
plausibl
although
unequivoc
repres
breakthrough
improv
need
partial
effect
expen
sive
lifelong
noncur
use
pathogenesi
ms
remain
unknown
evi
denc
implic
geneticenvironment
interact
critic
time
exposur
initi
factor
epidemiolog
studi
highlight
epsteinbarr
viru
low
plasma
level
vitamin
genet
studi
implic
sever
polymorph
variant
immun
respons
gene
obviou
clinic
outcom
reduct
mri
lesion
pro
tein
product
isg
probabl
mediat
effect
one
exampl
isg
product
form
inhibitori
associ
sphingosin
receptor
consequ
vivo
suppress
lymphocyt
exit
lymph
node
restrict
number
circul
lymphocyt
avail
cross
bloodbrain
barrier
reduct
express
matrix
metalloproteinas
activ
lymphocyt
increas
solubl
vascular
cell
adhes
molecul
svcam
level
plasma
also
identifi
assign
put
role
benefici
effect
patient
ms
expressionarray
studi
candid
gene
evalu
appli
without
region
abnorm
signal
brain
spinal
cord
detect
magnet
reson
imag
mri
indic
tissu
chang
relat
multipl
sclerosi
pathogen
process
depend
imag
techniqu
mri
chang
reflect
inflamm
demyelin
axon
destruct
scar
group
compound
belong
corticosteroid
famili
compound
either
natur
produc
hormon
synthet
affect
metabol
antiinflammatori
immunosuppress
effect
mani
synthet
glucocorticoid
exampl
dexamethason
use
clinic
medicin
antiinflammatori
drug
success
attempt
identifi
molecular
biomark
therapeut
effect
ms
develop
valid
outcom
measur
treatment
success
failur
aid
process
cancer
base
reduct
diseas
morbid
initi
regulatori
approv
market
chronic
b
hairi
cell
leukaemia
occur
within
year
clinic
introduct
result
close
collabor
academ
institut
govern
ment
industri
hairi
cell
leukaemia
chronic
myelogen
leukemia
cml
decreas
mar
row
infiltr
malign
cell
normal
peripher
haematolog
paramet
cml
addit
reduct
leukaem
cell
mass
decreas
result
cell
abnorm
activ
bcrabl
kinas
patient
cml
complet
cytogenet
respons
remiss
year
howev
surviv
advantag
compar
chemotherapi
cml
exceed
even
greater
effect
target
inhibitor
activ
bcrabl
kinas
imatinib
gleevec
novarti
newer
tyrosin
kinas
inhibitor
addit
hairi
cell
leukaemia
cml
thera
peutic
effect
caus
least
partial
diseas
regress
identifi
dozen
malign
includ
myeloma
lym
phoma
melanoma
renal
cell
bladder
carcinoma
kaposi
sarcoma
exampl
lymphoma
variou
histolog
bcell
tcell
pheno
type
effect
induc
tumour
regress
almost
half
patient
involv
studi
even
patient
previous
treat
chemotherapi
prolong
diseasefre
overal
surviv
intermedi
prognosi
lymphoma
result
combin
chemo
therapi
even
given
limit
period
random
multicent
trial
intern
phase
iii
trial
conduct
surviv
impact
confirm
meta
static
renal
carcinoma
like
cml
oral
activ
target
tyrosin
kinas
inhibitor
chang
natur
histori
renal
carcinoma
extend
surviv
metastat
diseas
inject
cure
metastat
malign
result
micrometastas
elimin
patient
highest
risk
recurr
surgic
remov
primari
tumour
effect
surgic
adjuv
murin
tumour
provid
rational
lead
pioneer
clinic
studi
suggest
benefit
impur
given
surgeri
osteosarcoma
surgic
adjuv
approach
basi
evalua
tion
patient
high
risk
recurr
melanoma
initi
benefici
effect
signific
pro
longat
diseasefre
surviv
larg
valid
combin
analys
multiinstitut
trial
subsequ
studi
includ
evalua
tion
pegyl
metaanalys
like
potent
physiolog
mediat
glucocorticoid
ifn
toxic
administ
pharmacolog
intent
dose
relat
particularli
difficult
high
dose
use
melanoma
initi
dose
malais
fever
chill
last
hour
domin
tachi
phylaxi
occur
subsequ
inject
fatigu
anorexia
aetiolog
understood
often
doselimit
chronic
administr
cer
ms
higher
dose
weight
loss
occur
may
signific
revers
elev
hepat
transaminas
may
occur
may
haematolog
effect
markedli
granulocytopaenia
like
ms
failur
fulli
understand
mecha
nism
antitumour
action
slow
devel
opment
suppress
mutat
polymorph
ifn
signal
mechan
malig
nant
cell
emerg
import
contributor
cer
develop
mutat
rnasel
associ
prostat
carcinoma
presenc
retroviru
xmrv
epigenet
genet
silenc
ifnsignal
isg
express
may
also
influenc
tumour
develop
revers
effect
like
basi
effect
ifn
andor
induc
murin
carcinogeninduc
tumour
may
contribut
effect
advanc
diseas
provid
ration
develop
tlr
agonist
box
import
research
question
futur
specif
role
multipl
isoform
interferon
ifn
play
host
defenc
new
role
identifi
ifn
system
protein
product
crosstalk
innat
cellular
immun
cellular
gene
product
avoid
activ
tolllik
receptor
tlr
pathway
microbi
gene
product
activ
effici
cell
type
differ
altern
signal
pathway
interact
jakstat
cell
tissu
specif
differ
molecular
respons
respons
differ
cell
differ
matur
exampl
stem
cell
senesc
cell
function
still
mani
uncharacter
ifnstimul
gene
isg
isg
import
specif
cellular
clinic
effect
way
activ
ifn
system
prove
therapeut
use
newli
human
papilloma
viru
hpv
associ
squamou
neoplasm
upper
airway
mechan
caus
difficult
spectrum
clinic
side
effect
fatigu
anorexia
ifn
play
bystand
pathogen
role
lupu
erythematosi
rheumatoid
arthriti
aplast
anaemia
low
highaffin
antibodi
ifn
protein
product
influenc
innat
immun
molecular
caus
resist
ifn
viral
diseas
multipl
sclerosi
cancer
helicas
proteas
augment
activ
ifn
hepat
b
viru
infect
antiangiogen
promot
methyl
inhibitor
increas
antitumour
activ
novel
receptor
agonist
antagonist
engin
specif
function
physicochem
rather
biolog
standard
develop
scientif
regulatori
comparison
smallmolecul
activ
ifninduc
protein
antivir
andor
antitumour
effect
effect
compon
ifn
system
prove
immunolog
adjuv
effect
oral
system
induc
identifi
f
c
u
n
n
v
r
l
chemoprevent
inde
tlr
agonist
appear
effect
alreadi
establish
role
treat
ment
malign
proven
effect
agonist
imiquimod
use
topic
basal
cell
carcinoma
exampl
furthermor
rel
clinic
safeti
establish
phosphorthio
oligoribonucelotid
agonist
induct
apoptosi
isg
product
trail
fa
identifi
mani
malign
cell
type
induct
immun
effector
cell
surfac
thu
sensit
tumour
cell
tcell
nk
cell
macrophagemedi
cytotox
tabl
intralesion
administr
basal
cell
carcinoma
increas
fa
express
correl
regress
increas
suscept
apoptosi
fa
activ
cytotox
chemotherapi
mani
cell
type
includ
melanoma
colorect
carcinoma
interact
inhibitor
apoptosi
xiap
isg
product
may
allow
fulli
activ
downstream
caspas
addit
isg
product
suppress
anoth
antiapoptot
protein
survivin
antitumour
activ
vivo
may
also
mediat
augment
lytic
activ
immun
effector
cell
enhanc
immunogen
tumour
cell
tcell
nkcell
traffick
expans
lytic
activ
promot
ifn
isg
furthermor
secret
activ
cell
tumour
micro
environ
addit
stimul
immun
effector
cell
ifn
critic
role
antigen
process
ing
present
discuss
cell
dendrit
cell
addit
upregul
tumourassoci
antigen
carcinoembryon
anti
gen
vitro
vivo
ifn
also
inhibit
angiogenesi
alter
stimuli
tumour
cell
directli
inhibit
endotheli
cell
inde
first
angiogen
inhibitor
identifi
endotheli
cell
inhibit
motil
undergo
coagul
necrosi
vitro
inhi
bition
angiogenesi
occur
vivo
within
hour
tumour
cell
inocul
suppress
basic
fibrob
last
growth
factor
bfgf
also
known
correl
reduc
vascular
tumour
growth
ifn
also
inhibit
vascular
endotheli
growth
factor
vegf
mrna
protein
express
regul
promot
mediat
angiogenesi
inhibit
vitro
vivo
angiogenesi
inhibitori
member
chemokin
famili
isg
endotheli
cell
isg
product
guanyl
bind
ing
protein
interferoninduc
kda
function
inflammatori
respons
factor
inhib
ite
endotheli
cell
prolifer
angiogenesi
part
mmp
clinic
prove
effect
treatment
infantil
haemangioma
haemangioblastoma
giant
cell
tumour
mandibl
kaposi
sarcoma
thu
induct
isg
function
angiostat
inhibitor
coupl
second
ari
downregul
angiogen
factor
may
contribut
antitumour
effect
ifn
provid
fundament
cellular
defenc
mechan
viral
infect
cancer
thu
critic
import
health
anim
human
clinic
effect
limit
viru
replic
reduc
tumour
cell
mass
control
diseas
symptom
prolong
surviv
ifn
licens
world
wide
treatment
variou
viral
malign
immun
disord
market
sale
approach
us
billion
part
innat
immun
respons
ifn
princip
cytokin
block
viral
replic
action
specif
isg
also
particularli
mediat
critic
element
cellular
immun
respons
recur
bacteri
infect
chronic
granuloma
tou
diseas
mycobacteria
biolog
effect
ifn
mediat
action
isg
understand
function
gene
may
lead
efficaci
anticanc
antivir
therapeut
exampl
certain
ifnregul
protein
oa
rnasel
pkr
exist
either
latent
inact
activ
state
could
target
potent
anti
tumour
andor
antivir
effect
fig
ifn
therefor
reach
effect
ness
anticip
earli
virologist
antivir
spectrum
clinic
effect
rna
dna
virus
prototyp
biolog
respons
modifi
oncolog
prove
effect
suppress
manifest
ms
studi
ifn
result
fundament
insight
cellular
signal
mecha
nism
innat
acquir
immun
addit
therapeut
use
improv
qualiti
quan
titi
life
million
patient
worldwid
howev
fulli
realiz
potenti
mani
question
remain
unansw
box
exemplifi
recent
publica
tion
investig
enabl
ifn
even
greater
impact
biomedicin
isaac
